secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2025-07-28T23:59:59+00:00
Accession:  0000950170-25-099184
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyne Q2 net loss $110.9M extends cash runway into Q3 2027 on $215M offering
---------------------------------------------------------------------------

- Net loss $110.9M ($0.97/sh) vs $65.1M ($0.70) in Q2 2024; R&D expenses $99.2M.
- Cash $683.9M; July offering net $215.2M; Hercules $100M initial loan; runway into Q3 2027.
- DYNE-251 DMD registrational cohort enrolled (32 pts); data late 2025; potential BLA early 2026.
- DYNE-101 DM1 FDA Breakthrough Therapy; 60-pt cohort enrollment Q4 2025; data mid-2026; BLA late 2026.
- Hercules $275M senior secured loan; 5 tranches; milestones-based drawdown; final tranche subject to approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000095017025099184/0000950170-25-099184-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000095017025099184/dyn-20250728.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-099184

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer